Dr. Lloyd E. Damon is a hematologist who cares for patients with blood cancers, such as leukemia, as well as those with noncancerous blood conditions, such as clotting disorders, low or high blood cell counts, and iron deficiency or overload. His expertise includes care of patients who have undergone stem cell transplantation.
Damon's past research has focused on chemotherapy toxicity and chemotherapy dosing for stem cell transplantation. He was also active in early development of certain immunotherapy agents, such as rituximab (a monoclonal antibody used for some blood cancers) and investigational vaccines for leukemia. He has served as a UCSF principal investigator on national trials looking at issues in allogeneic stem cell transplantation (which uses cells from a donor rather than the patient's own cells). He has now retired from research and is on faculty recall status as he continues to care for hematology patients.
Damon earned his medical degree at the University of Michigan. He completed an internal medicine residency and a fellowship in hematology and oncology at UCSF, joining the faculty in 1988.
Damon is a UCSF Department of Medicine master clinician and has received the Exceptional Physician Award. From 2008 to 2018, he was director of hematology and blood transplantation. In addition, he has served as deputy chief of the hematology and oncology division. Beyond his leadership roles at UCSF, he was a founding member of the UC Hematologic Malignancies Consortium and continues to serve on its steering committee.
5.0